Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05863052 · ClinicalTrials.gov registry record

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

A clinical trial of Non-Small Cell Lung Cancer and Melanoma, sponsored by University of Oklahoma.

Active
Registry status
72
Enrollment target
6
Study locations

NCT05863052: Active study of Non-Small Cell Lung Cancer and Melanoma, sponsored by University of Oklahoma.

NCT05863052 is a study of Non-Small Cell Lung Cancer and Melanoma that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 72 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05863052, a study of Non-Small Cell Lung Cancer and Melanoma, is active but no longer recruiting, sponsored by University of Oklahoma.

ACTIVE NOT RECRUITING
Registry status
72 participants
Enrollment target
6
Study locations

Study Summary

The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.

Primary Outcome

Evaluating progression free survival of American Indian population vs. White population who were treated with immunotherapy

Interventions

  • BIOLOGICAL Immunotherapy

Study Locations (6)

South Dakota

  • Monument Health Cancer Care Institute - Rapid City
  • Avera Cancer Institute - Sioux Falls

Arizona

  • Arizona Cancer Center at the Unvieristy of Arizona - Tucson

New Mexico

  • University of New Mexico Comprehensive Cancer Center - Albuquerque

Oklahoma

  • Stephenson Cancer Center - Oklahoma City

Utah

  • Huntsman Cancer Institute at the University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2022-01-31
Est. Completion 2027-12
University of Oklahoma

358 total trials

What the registry record for NCT05863052 still lists

NCT05863052 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (89% lower).

The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Immunotherapy is the first listed.

NCT05863052 lists 6 locations in 5 states (South Dakota, Arizona, New Mexico).

Frequently Asked Questions

What is clinical trial NCT05863052 about?

NCT05863052 is a clinical study titled "Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population". The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventiona...

What is the current status of trial NCT05863052?

This trial is currently active not recruiting. The enrollment target is 72 participants. The study started on 2022-01-31. Estimated completion is 2027-12.

What conditions does trial NCT05863052 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma, Metastatic Solid Tumor, Gastrointestinal Cancer.

What interventions are being tested in trial NCT05863052?

The interventions under investigation include: Immunotherapy (BIOLOGICAL).

Who is sponsoring clinical trial NCT05863052?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05863052 being conducted?

This trial has 6 study locations across Arizona, New Mexico, Oklahoma, South Dakota, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05863052's enrollment target sits among peer trials

72 284th of 454 higher than 170 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02359253 · 72 participants · NA

    Robot Aided Rehabilitation - Intervention

  • NCT02962661 · 72 participants · Phase 1

    Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines

  • NCT03113643 · 72 participants · Phase 1

    SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

  • NCT03187535 · 72 participants · NA

    Effect of TEAS on PONV After Spinal Surgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05863052, the US trial registry maintained by the National Library of Medicine. NCT05863052 (small enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.